| 抗滤泡性淋巴瘤的新药Copanlisib |
| |
| 引用本文： | 张恩景,邓体瑛.抗滤泡性淋巴瘤的新药Copanlisib[J].现代药物与临床,2018,41(5):934-936. |
| |
| 作者姓名： | 张恩景 邓体瑛 |
| |
| 作者单位： | 武汉大学同仁医院 药学部, 湖北 武汉 430060,武汉市第一医院 临床药学部, 湖北 武汉 430022 |
| |
| 摘 要： | 滤泡性淋巴瘤是常见的恶性血液病，有较高的发病率，与磷脂酰肌醇-3-激酶（PI3K）信号通路的失调相关。Copanlisib是拜耳公司研制的抗滤泡性淋巴瘤的孤儿药，也是全球首个泛I类磷脂酰肌醇-3-激酶高效选择性抑制剂，对复发性或难治性滤泡性淋巴瘤成人患者有良好的疗效。它的有效性和安全性已被临床试验充分证实，于2017年9月获得美国FDA的批准在临床使用。概述了Copanlisib的药效学、药动学、临床试验和安全性等研究情况。
|
| 关 键 词： | Copanlisib 磷脂酰肌醇-3-激酶抑制剂 滤泡性淋巴瘤 孤儿药 |
| 收稿时间： | 2017/12/7 0:00:00 |
Copanlisib as a novel drug treating follicular lymphoma |
| |
| ZHANG Enjing and DENG Tiying.Copanlisib as a novel drug treating follicular lymphoma[J].Drugs & Clinic,2018,41(5):934-936. |
| |
| Authors: | ZHANG Enjing and DENG Tiying |
| |
| Institution: | Pharmacy Department, Tongren Hospital of Wuhan University, Wuhan 430060, China and Department of Pharmacy, Wuhan No.1 Hospital, Wuhan 430022, China |
| |
| Abstract: | Follicular lymphoma is a common malignant hematonosis with comparatively high morbidity, which is linked closely with dysregulated phosphatidylinositol 3-kinases (PI3Ks) signal pathway. Copanlisib developed by Bayer Group is an orphan drug treating follicular lymphoma as well as the world''s first pan-class I PI3Ks inhibitor featuring the high selectivity. It demonstrated a potent activity for the treatment of adult patients with relapsed follicular lymphoma. Clinical trials have demonstrated its efficacy and safety, and the U.S. Food and Drug Administration (FDA) officially approved its clinical application in September 2017. In the article, authors mainly described its pharmacodynamics, pharmacokinetics, clinical trials, and safety. |
| |
| Keywords: | Copanlisib phosphatidylinositol 3-kinases (PI3Ks) inhibitor follicular lymphoma orphan drug |
|
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
| 点击此处可从《现代药物与临床》下载免费的PDF全文 |
